In the five years since the introduction of CRISPR/Cas9, a fast and highly accurate method of editing DNA in living organisms, the tool has revolutionized medical research, drug development, and agriculture. But the process still requires a time-consuming effort to identify and build snippets of “guide RNA” that locate the specific genes to be cut or modified. Synthego, launched by brothers Paul and Michael Dabrowski in 2016, makes it easier, offering kits of synthetic guide RNA optimized to target DNA in species ranging from bacteria to humans. Through intensive automation, Synthego has cut the cost of synthetic guide RNA by up to 80% and drastically sped up production—customers can place an online order and get their package within days instead of the weeks it might take to build it themselves. Synthego has more than 1,000 customers in more than 30 countries, and works with eight of the world’s top-10 commercial biopharma companies and most of the world’s top biology universities. In 2017, it brought on Jennifer Doudna, a co-discoverer of CRISPR, as an investor, and launched a grant to give away $160,000 worth of synthetic guide RNA to enable research in key application areas.